Illumina to cut $100M in fiscal 2025 costs

Illumina plans $100M cost savings to cope with China ban
The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.
Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban
Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego-based Illumina is lowering its 2025 guidance to $4.
Illumina aims to cut $100M in costs following China import ban
Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue from China, after the country banned the importation of its DN | Illumina also lowered its annual financial forecast,
Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for high-single-digit growth by 2027.
Illumina sees 2025 EPS of $4.50 after China ban, consensus $4.51
Illumina (ILMN) responded to the March 4 notice from the China Ministry of Commerce that the company is not permitted to export sequencing
China bans Illumina sequencer imports as US trade war intensifies
GlobalData’s senior medical analyst says the ban will add to a downward trend for Illumina in the Chinese market.
Illumina lowers outlook due to China sales ban, to cut $100 million in costs
Illumina on Monday lowered its annual forecast and said it plans to cut $100 million in spending after China announced a ban on imports of its genetic sequencing instruments. The company said it now expects 2025 adjusted profit of about $4.
Illumina lowers guidance, cuts spending to mitigate China ban on its gene sequencers
Illumina (NASDAQ:ILMN) on Monday lowered its adjusted profit outlook and cut spending cost for 2025 as the company grapples with Chinese ban on its gene sequencers. Illumina now expects fiscal 2025 non-GAAP diluted EPS of about $4.
China Targets San Diego Biotech Firm in Broadening Blacklist
In a sign it is willing to go further in responding to President Trump’s tariffs, Beijing blocked more American companies ...
Illumina price target lowered to $128 from $247 at RBC Capital
RBC Capital lowered the firm’s price target on Illumina (ILMN) to $128 from $247 but keeps an Outperform rating on the shares. The company’s ...
Illumina addresses recent developments in China
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today responded to the March 4, 2025 notice from the China Ministry of Commerce ("MOFCOM") that Illumina is not permitted to export ...
What's Left of Illumina's China Business After Tariff Retaliation: Heard on the Street
Illumina shareholders received a warning shot. In response to President Trump’s initial tariff measures, the Chinese ...
Illumina cuts workforce at San Diego headquarters
Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with ...
Why Illumina, Inc. (ILMN) Is Plunging So Far In 2025
We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...